These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 25864227)
1. Obeticholic acid: expanding the therapeutic landscape of NASH. Arrese M; Cabrera D; Barrera F Ann Hepatol; 2015; 14(3):430-2. PubMed ID: 25864227 [No Abstract] [Full Text] [Related]
2. NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more? Ray K Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):1. PubMed ID: 25421586 [No Abstract] [Full Text] [Related]
4. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. Polyzos SA; Kountouras J; Mantzoros CS Metabolism; 2020 Mar; 104():154144. PubMed ID: 31930974 [No Abstract] [Full Text] [Related]
5. Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost. Musso G Hepatology; 2015 Jun; 61(6):2104-6. PubMed ID: 25753820 [No Abstract] [Full Text] [Related]
8. Trials of obeticholic acid for non-alcoholic steatohepatitis. Musso G; Cassader M; Gambino R Lancet; 2015 Jul; 386(9988):27. PubMed ID: 26169860 [No Abstract] [Full Text] [Related]
9. Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply. Neuschwander-Tetri BA; Van Natta ML; Tonascia J; Brunt EM; Kleiner DE Lancet; 2015 Jul; 386(9988):28-29. PubMed ID: 26169861 [No Abstract] [Full Text] [Related]
10. Obeticholic acid for the treatment of nonalcoholic steatohepatitis. Shah RA; Kowdley KV Expert Rev Gastroenterol Hepatol; 2020 May; 14(5):311-321. PubMed ID: 32241197 [TBL] [Abstract][Full Text] [Related]
11. Is obeticholic Acid the solution to nonalcoholic steatohepatitis? Wong VW; Wong GL; Chan FK Gastroenterology; 2015 Apr; 148(4):851-2. PubMed ID: 25726736 [No Abstract] [Full Text] [Related]
12. Obeticholic acid (Ocaliva) for primary biliary cholangitis. Med Lett Drugs Ther; 2017 Mar; 59(1517):53-55. PubMed ID: 28323811 [No Abstract] [Full Text] [Related]
13. The NASH drug dash. Chi KR Nat Rev Drug Discov; 2015 Jul; 14(7):447-8. PubMed ID: 26129791 [No Abstract] [Full Text] [Related]
15. Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies. Jahn D; Rau M; Wohlfahrt J; Hermanns HM; Geier A Dig Dis; 2016; 34(4):356-63. PubMed ID: 27170389 [TBL] [Abstract][Full Text] [Related]
16. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. Makri E; Cholongitas E; Tziomalos K World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393 [TBL] [Abstract][Full Text] [Related]
17. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives. Gitto S; Guarneri V; Sartini A; Andreone P Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):165-171. PubMed ID: 29082798 [TBL] [Abstract][Full Text] [Related]
18. [Pharmacological treatment of NASH]. Serfaty L Presse Med; 2019 Dec; 48(12):1489-1495. PubMed ID: 31757735 [TBL] [Abstract][Full Text] [Related]
19. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Gawrieh S; Chalasani N Clin Liver Dis; 2018 Feb; 22(1):189-199. PubMed ID: 29128056 [TBL] [Abstract][Full Text] [Related]
20. Editorial: weight change, liver histology and the metabolic effects of obeticholic acid in NASH. Eslam M; George J Aliment Pharmacol Ther; 2018 Apr; 47(7):1038-1039. PubMed ID: 29512910 [No Abstract] [Full Text] [Related] [Next] [New Search]